Arbejdsmarkedets Tillaegspension Buys 59,161 Shares of Medtronic PLC $MDT

Key Points

• Arbejdsmarkedets Tillaegspension increased its Medtronic stake by 25.3% in the first quarter, buying 59,161 additional shares and bringing its total holding to 292,638 shares worth about $25.4 million.
• Medtronic reported better-than-expected quarterly results, with earnings per share of $1.55 versus the $1.54 estimate and revenue of $9.81 billion, helped by 9.9% year-over-year revenue growth.
• The company raised its quarterly dividend to $0.72 per share, implying an annualized payout of $2.88 and a 3.4% yield, while analysts remain broadly positive with a consensus Moderate Buy rating.

Arbejdsmarkedets Tillaegspension lifted its stake in Medtronic PLC (NYSE:MDT - Free Report) by 25.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 292,638 shares of the medical technology company's stock after purchasing an additional 59,161 shares during the period. Arbejdsmarkedets Tillaegspension's holdings in Medtronic were worth $25,357,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of MDT. Monetary Solutions Ltd purchased a new position in shares of Medtronic in the fourth quarter worth $27,000. Lodestone Wealth Management LLC bought a new position in shares of Medtronic during the fourth quarter worth $27,000. Anfield Capital Management LLC grew its stake in Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company's stock valued at $27,000 after acquiring an additional 230 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in Medtronic during the fourth quarter valued at $29,000. Finally, GoalVest Advisory LLC bought a new stake in Medtronic in the 4th quarter valued at $29,000. Institutional investors own 82.06% of the company's stock.

Medtronic Stock Down 0.1%

Shares of NYSE:MDT opened at $83.78 on Monday. The company has a market cap of $107.24 billion, a price-to-earnings ratio of 22.46, a PEG ratio of 2.25 and a beta of 0.56. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The company has a 50-day moving average price of $79.11 and a 200 day moving average price of $88.46.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion for the quarter, compared to analysts' expectations of $9.62 billion. During the same period in the previous year, the firm posted $1.62 earnings per share. The firm's revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities research analysts predict that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 3.4%. This is a positive change from Medtronic's previous quarterly dividend of $0.71. The ex-dividend date is Friday, June 26th. Medtronic's dividend payout ratio (DPR) is presently 77.21%.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president owned 37,227 shares of the company's stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.26% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Royal Bank Of Canada reiterated an "outperform" rating and issued a $118.00 price target on shares of Medtronic in a research note on Thursday, June 4th. The Goldman Sachs Group reduced their target price on Medtronic from $84.00 to $83.00 and set a "neutral" rating on the stock in a report on Thursday, June 4th. BTIG Research upgraded Medtronic from a "neutral" rating to a "buy" rating and set a $90.00 target price on the stock in a research report on Wednesday, June 3rd. Leerink Partners dropped their price target on Medtronic from $117.00 to $104.00 and set an "outperform" rating for the company in a research note on Thursday, June 4th. Finally, Rothschild & Co Redburn cut their price target on Medtronic from $111.00 to $106.00 and set a "buy" rating for the company in a report on Friday, June 5th. Seventeen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $98.17.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: TD Cowen cut its price target on Medtronic to $100 from $119 but kept a buy rating, signaling the stock still has meaningful upside from current levels. TD Cowen lowers price target on Medtronic
• Positive Sentiment: Another recent bullish note said Medtronic’s guidance is conservative and “built to be beaten,” highlighting strong fiscal 2026 revenue growth and potential upside catalysts from the MiniMed separation, tariff refunds, and payment relief. Medtronic guidance built to be beaten
• Positive Sentiment: Another Seeking Alpha article argued Medtronic is undervalued and that tailwinds are just beginning, reinforcing the idea that investors may be underappreciating the company’s growth potential. Medtronic undervalued and tailwinds just getting started
• Positive Sentiment: Citi also reportedly initiated or reiterated a buy view on Medtronic, adding to the wave of favorable analyst sentiment. Medtronic receives a buy from Citi
• Neutral Sentiment: Medtronic disclosed a voluntary global recall of its Octopus 4 Tissue Stabilizer after an assembly issue affecting 590 units. The issue appears limited, but recalls can create short-term investor caution. Medtronic recalls Octopus 4 Tissue Stabilizer
• Neutral Sentiment: Separate valuation pieces on Medtronic suggest the stock remains cheap relative to fundamentals, but these are more interpretation than hard catalysts for the share price. Medtronic stock could be undervalued

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.